Nag, Anwesha

Genetic and transcriptional evolution alters cancer cell line drug response

Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature

Cancer Genomics and DiagnosticsCancer Cells and Metastasis

Cited by 931

Cas9 activates the p53 pathway and selects for p53-inactivating mutations

Enache, O. M., Rendo, V., Abdusamad, M., Lam, D., Davison, D., Pal, S., Currimjee, N., Hess, J., Pantel, S., Nag, A., et al. (2020) · Nature Genetics

CRISPR and Genetic EngineeringCancer-related Molecular Pathways

Cited by 285

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 149

Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Abbou, S., Klega, K., Tsuji, J., Tanhaemami, M., Hall, D., Barkauskas, D. A., Krailo, M. D., Cibulskis, C., Nag, A., Thorner, A. R., et al. (2023) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 44

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533

Madanat-Harjuoja, L. M., Renfro, L. A., Klega, K., Tornwall, B., Thorner, A. R., Nag, A., Dix, D., Dome, J. S., Diller, L. R., Fernandez, C. V., et al. (2022) · Journal of Clinical Oncology

Renal and related cancersCancer Genomics and Diagnostics

Cited by 41